Prostate Cancer Disparities and Management in Southern Africa: Insights into Practices, Norms and Values

References

• Hamdi Y, Abdeljaoued-Tej I, Zatchi AA, et al. Cancer in Africa: the untold story. Front Oncol. 2021;11:650117. doi:10.3389/fonc.2021.650117
   PubMed Web of Science ®Google Scholar
• Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339(6122):961–965. doi:10.1126/science.1230413
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Devesa SS, Chang BL, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer. 2013;2013:560857. doi:10.1155/2013/560857
   PubMedGoogle Scholar
• World Health Organization. Global cancer observatory: cancer Today; 2014. Available from: https://gco.iarc.fr. Accessed December 7, 2022.
   Google Scholar
• Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW Jr. Cancer statistics by race and ethnicity. CA Cancer J Clin. 1998;48(1):31–48. doi:10.3322/canjclin.48.1.31
   PubMed Web of Science ®Google Scholar
• Marima R, Hull R, Mathabe K, et al. Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets. Am J Cancer Res. 2021;11(4):1012–1030.
   PubMed Web of Science ®Google Scholar
• Bentley AR, Callier S, Rotimi C. The emergence of genomic research in Africa and new frameworks for equity in biomedical research. Ethn Dis. 2019;29(Suppl 1):179–186. doi:10.18865/ed.29.S1.179
   PubMed Web of Science ®Google Scholar
• Marima R, Hull R, Mbeje M, et al. Role of precision oncology in type II endometrial and prostate cancers in the African population: global cancer genomics disparities. Int J Mol Sci. 2022;23(2). doi:10.3390/ijms23020628
   PubMed Web of Science ®Google Scholar
• Corbex M, Bouzbid S, Boffetta P. Features of breast cancer in developing countries, examples from North-Africa. Eur J Cancer. 2014;50(10):1808–1818. doi:10.1016/j.ejca.2014.03.016
   PubMed Web of Science ®Google Scholar
• Tindall EA, Monare LR, Petersen DC, et al. Clinical presentation of prostate cancer in black South Africans. Prostate. 2014;74(8):880–891. doi:10.1002/pros.22806
   PubMed Web of Science ®Google Scholar
• Ramaliba TM, Sithole N, Ncinitwa A, Somdyala NIM. Prostate cancer patterns and trends in the Eastern Cape Province of South Africa; 1998–2017. Original research. Front Public Health. 2022;10. doi:10.3389/fpubh.2022.882586
   PubMed Web of Science ®Google Scholar
• Babb C, Urban M, Kielkowski D, Kellett P. Prostate cancer in South Africa: pathology based national cancer registry data (1986–2006) and mortality rates (1997–2009). Prostate Cancer. 2014;2014:419801. doi:10.1155/2014/419801
   PubMedGoogle Scholar
• Ngcamphalala C, Östensson E, Ginindza TG. The economic burden of prostate cancer in Eswatini. BMC Health Serv Res. 2022;22(1):483. doi:10.1186/s12913-022-07817-6
   PubMed Web of Science ®Google Scholar
• Stefan DC. Cancer care in Africa: an overview of resources. J Glob Oncol. 2015;1(1):30–36. doi:10.1200/JGO.2015.000406
   PubMedGoogle Scholar
• Vanderpuye V, Hammad N, Martei Y, et al. Cancer care workforce in Africa: perspectives from a global survey. Infect Agent Cancer. 2019;14(1):1–8. doi:10.1186/s13027-019-0227-8
   PubMed Web of Science ®Google Scholar
• Ebell MH, Thai TN, Royalty KJ. Cancer screening recommendations: an international comparison of high income countries. Public Health Rev. 2018;39:7. doi:10.1186/s40985-018-0080-0
   PubMed Web of Science ®Google Scholar
• Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388–1400. doi:10.1002/ijc.29894
   PubMed Web of Science ®Google Scholar
• Screening for prostate cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2008;149(3):185–191. doi:10.7326/0003-4819-149-3-200808050-00008
   PubMed Web of Science ®Google Scholar
• Seraphin T, Joko Fru YW, Kamaté B, et al. Rising prostate cancer incidence in sub-Saharan Africa: a trend analysis of data from the African cancer registry network. Cancer Epidemiol Biomarkers Prev. 2020;30:158–165. doi:10.1158/1055-9965.EPI-20-1005
   PubMed Web of Science ®Google Scholar
• Cassell A, Yunusa B, Jalloh M, et al. Management of advanced and metastatic prostate cancer: a need for a sub-saharan guideline. J Oncol. 2019;2019:1785428. doi:10.1155/2019/1785428
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Devesa SS, Chang B-L, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer. 2013;2013:560857. doi:10.1155/2013/560857
   PubMedGoogle Scholar
• Lajous M, Cooperberg MR, Rider J, et al. Prostate cancer screening in low- and middle-income countries: the Mexican case. Salud Publica Mex. 2019;61(4):542–544. doi:10.21149/10373
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Eng J Med. 2004;350(22):2239–2246. doi:10.1056/NEJMoa031918
   PubMed Web of Science ®Google Scholar
• Preston MA, Batista JL, Wilson KM, et al. Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J Clin Oncol. 2016;34(23):2705–2711. doi:10.1200/jco.2016.66.7527
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023. doi:10.1136/bmj.f2023
   PubMed Web of Science ®Google Scholar
• National Institute for H, Clinical E. Prostate Cancer: Diagnosis and Treatment (CG 175). National Institute for Health and Care Excellence London; 2014.
   Google Scholar
• Gilbert R, Tilling K, Martin RM, et al. Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. Cancer Causes Control. 2018;29(3):383–388. doi:10.1007/s10552-018-1014-3
   PubMed Web of Science ®Google Scholar
• Shah SC, Kayamba V, Peek RM Jr, Heimburger D. Cancer control in low- and middle-income countries: is it time to consider screening? J Glob Oncol. 2019;5:1–8. doi:10.1200/jgo.18.00200
   Web of Science ®Google Scholar
• Washington CM, Leaver DT. Principles and Practice of Radiation Therapy-e-Book. Elsevier Health Sciences; 2015.
   Google Scholar
• Loeb S, Zhou Q, Siebert U, et al. Active surveillance versus watchful waiting for localized prostate cancer: a model to inform decisions. Eur Urol. 2017;72(6):899–907. doi:10.1016/j.eururo.2017.07.018
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016;4(3):404–411. doi:10.1111/andr.12186
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–240. doi:10.3322/canjclin.22.4.232
   PubMedGoogle Scholar
• Heemers HV. Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities? Int J Biol Sci. 2014;10(6):576–587. doi:10.7150/ijbs.8479
   PubMed Web of Science ®Google Scholar
• Liang T, Heiss CE. Inhibition of 5 alpha-reductase, receptor binding, and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza-steroid. J Biol Chem. 1981;256(15):7998–8005. doi:10.1016/S0021-9258(18)43378-9
   PubMed Web of Science ®Google Scholar
• Phillips R. Novel targeting of androgen signalling in CRPC. Nat Rev Urol. 2014;11(6):303. doi:10.1038/nrurol.2014.107
   PubMedGoogle Scholar
• Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5(3):280–285. doi:10.1038/6495
   PubMed Web of Science ®Google Scholar
• Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res. 2001;7(6):1773–1781.
   PubMed Web of Science ®Google Scholar
• Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 2002;277(9):7076–7085. doi:10.1074/jbc.M108255200
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Singh S, Srivastava SK, et al. Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br J Cancer. 2014;110(8):2000–2010. doi:10.1038/bjc.2014.141
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Singh S, Srivastava SK, Honkanen RE, Reed E, Singh AP. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther. 2011;10(5):720–731. doi:10.1158/1535-7163.Mct-10-1096
   PubMed Web of Science ®Google Scholar
• Huang J, Jia J, Tong Q, et al. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy. Tumour Biol. 2015;36(3):1589–1594. doi:10.1007/s13277-014-2748-5
   PubMedGoogle Scholar
• Srivastava SK, Bhardwaj A, Singh S, et al. Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis. 2012;33(6):1149–1157. doi:10.1093/carcin/bgs134
   PubMed Web of Science ®Google Scholar
• Fradet A, Bouchet M, Delliaux C, et al. Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. Oncotarget. 2016;7(47):77071–77086. doi:10.18632/oncotarget.12787
   PubMedGoogle Scholar
• Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate. 2018;78(1):2–10. doi:10.1002/pros.23446
   PubMed Web of Science ®Google Scholar
• Hu J, Chen Q. The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside. Int Urol Nephrol. 2017;49(3):369–380. doi:10.1007/s11255-016-1476-8
   PubMed Web of Science ®Google Scholar
• Puhr M, Hoefer J, Eigentler A, et al. The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy. Clin Cancer Res. 2018;24(4):927–938. doi:10.1158/1078-0432.Ccr-17-0989
   PubMed Web of Science ®Google Scholar
• Hayes VM, Bornman MSR. Prostate cancer in Southern Africa: does Africa hold untapped potential to add value to the current understanding of a common disease? J Glob Oncol. 2018;4:1–7. doi:10.1200/JGO.2016.008862
   Web of Science ®Google Scholar
• Cassell A, Yunusa B, Jalloh M, et al. A review of localized prostate cancer: an African perspective. World J Oncol. 2019;10(4–5):162–168. doi:10.14740/wjon1221
   PubMedGoogle Scholar
• Olender J, Lee NH. Role of alternative splicing in prostate cancer aggressiveness and drug resistance in African Americans. Adv Exp Med Biol. 2019;1164:119–139. doi:10.1007/978-3-030-22254-3_10
   PubMed Web of Science ®Google Scholar
• Cooperberg MR. Re-examining racial disparities in prostate cancer outcomes. J Clin Oncol. 2013;31(24):2979–2980. doi:10.1200/jco.2013.50.7723
   PubMed Web of Science ®Google Scholar
• Government SA Regulations relating to categories of hospitals. 469. Available from: https://www.gov.za/documents/national-health-act. Accessed December 7, 2022.
   Google Scholar
• Government SA. Regional, tertiary and central hospital services. Republic of South Africa;2015 Available from: https://www.health.gov.za/index.php/nhi/category/267-nhi-016?download=1142:annexure-b-tertiary-services-definitions-package-of-care-december-2015. Accessed December 7, 2022.
   Google Scholar
• Koce F, Randhawa G, Ochieng B. Understanding healthcare self-referral in Nigeria from the service users’ perspective: a qualitative study of Niger state. BMC Health Serv Res. 2019;19(1):1–14. doi:10.1186/s12913-019-4046-9
   PubMed Web of Science ®Google Scholar
• King AJ, Evans M, Moore TH, et al. Prostate cancer and supportive care: a systematic review and qualitative synthesis of men’s experiences and unmet needs. Eur J Cancer Care. 2015;24(5):618–634. doi:10.1111/ecc.12286
   PubMed Web of Science ®Google Scholar
• Rüesch P, Schaffert R, Fischer S, et al. Information needs of early-stage prostate cancer patients: within- and between-group agreement of patients and health professionals. Support Care Cancer. 2014;22(4):999–1007. doi:10.1007/s00520-013-2052-8
   PubMed Web of Science ®Google Scholar
• Chauhan M, Holch P, Holborn C. Assessing the information and support needs of radical prostate cancer patients and acceptability of a group-based treatment review: a questionnaire and qualitative interview study. J Radiother Pract. 2018;17(2):151–161. doi:10.1017/S1460396917000644
   Web of Science ®Google Scholar
• Kassianos AP, Raats MM, Gage H. An exploratory study on the information needs of prostate cancer patients and their partners. Health Psychol Res. 2016;4(1):4786. doi:10.4081/hpr.2016.4786
   PubMedGoogle Scholar
• Feldman-Stewart D, Capirci C, Brennenstuhl S, et al. Information needs of early-stage prostate cancer patients: a comparison of nine countries. Radiother Oncol. 2010;94(3):328–333. doi:10.1016/j.radonc.2009.12.038
   PubMed Web of Science ®Google Scholar
• Dale J, Jatsch W, Hughes N, Pearce A, Meystre C. Information needs and prostate cancer: the development of a systematic means of identification. BJU Int. 2004;94(1):63–69. doi:10.1111/j.1464-410X.2004.04902.x
   PubMed Web of Science ®Google Scholar
• Leeds-Hurwitz W. Social construction of reality. Encyc Comm Theor. 2009;2:891–894.
   Google Scholar
• Miller G. Reconsidering Social Constructionism: Social Problems and Social Issues. Routledge; 2017.
   Google Scholar
• Ezeugwu CR, Ojedokun O. Masculine norms and mental health of African men: what can psychology do? Heliyon. 2020;6(12):e05650. doi:10.1016/j.heliyon.2020.e05650
   PubMed Web of Science ®Google Scholar
• Mofolo N, Betshu O, Kenna O, et al. Knowledge of prostate cancer among males attending a urology clinic, a South African study. SpringerPlus. 2015;4:67. doi:10.1186/s40064-015-0824-y
   PubMedGoogle Scholar
• Nzama N. Masculinity and men’s health seeking behaviours amongst black/African men: the case of Durban, KwaZulu-Natal, South Africa; 2013.
   Google Scholar
• Tetteh DA, Faulkner SL. Sociocultural factors and breast cancer in sub-Saharan Africa: implications for diagnosis and management. Womens Health. 2016;12(1):147–156. doi:10.2217/whe.15.76
   Google Scholar
• Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870–e191870. doi:10.1001/jamaoncol.2019.1870
   PubMed Web of Science ®Google Scholar
• Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc. 1996;88(10):630–634.
   PubMed Web of Science ®Google Scholar
• Wissing MD, Kluetz PG, Ning YM, et al. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993–2013. Cancer. 2014;120(19):3025–3032. doi:10.1002/cncr.28809
   PubMed Web of Science ®Google Scholar
• Branson RD, Davis K Jr, Butler KL. African Americans’ participation in clinical research: importance, barriers, and solutions. Am J Surg. 2007;193(1):32–39. doi:10.1016/j.amjsurg.2005.11.007
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Harris Y, Burnett B, Bonecutter FJ. The recruitment triangle: reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial. An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc. 1998;90(3):141–145.
   PubMed Web of Science ®Google Scholar
• Allen M. The dilemma for women of color in clinical trials. J Am Med Womens Assoc. 1994;49(4):105–109.
   Google Scholar
• O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15(15):4806–4814. doi:10.1158/1078-0432.Ccr-09-0344
   PubMed Web of Science ®Google Scholar
• Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008;99(11):1757–1762. doi:10.1038/sj.bjc.6604721
   PubMed Web of Science ®Google Scholar
• Mulder NJ, Adebiyi E, Adebiyi M, et al. Development of bioinformatics infrastructure for genomics research. Glob Heart. 2017;12(2):91–98. doi:10.1016/j.gheart.2017.01.005
   PubMed Web of Science ®Google Scholar
• Nordling L. Putting Genomes to Work in Africa. Nature. 2017;544:20–22.
   PubMed Web of Science ®Google Scholar
• Mukhwana AM, Kariuki T, Kay S, Silva AJ, Kirkland J. The African academy of sciences research management programme in Africa. J Res Manag Gov. 2019;2(1):31–33.
   Google Scholar
• Hoppe TA, Litovitz A, Willis KA, et al. Topic choice contributes to the lower rate of NIH awards to African-American/black scientists. Sci Adv. 2019;5(10):eaaw7238.
   PubMed Web of Science ®Google Scholar
• Carnethon MR, Kershaw KN, Kandula NR. Disparities research, disparities researchers, and health equity. JAMA. 2020;323(3):211–212.
   PubMed Web of Science ®Google Scholar
• Ginther DK, Schaffer WT, Schnell J, et al. Race, ethnicity, and NIH research awards. Science. 2011;333(6045):1015–1019.
   PubMed Web of Science ®Google Scholar
• Savitt TL. The use of blacks for medical experimentation and demonstration in the Old South. J South Hist. 1982;48(3):331–348.
   PubMed Web of Science ®Google Scholar
• Sivaram S, Perkins S, He M, et al. Building capacity for global cancer research: existing opportunities and future directions. J Cancer Educ. 2021;36(Suppl 1):5–24. doi:10.1007/s13187-021-02043-w
   PubMed Web of Science ®Google Scholar
• LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ. Alcohol and cancer: a statement of the American society of clinical oncology. J Clin Oncol. 2018;36(1):83–93.
   PubMed Web of Science ®Google Scholar
• Tan S-H, Petrovics G, Srivastava S. Prostate cancer genomics: recent advances and the prevailing underrepresentation from racial and ethnic minorities. Int J Mol Sci. 2018;19(4):1255.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Walsh T, Gulsuner S, et al. Inherited breast cancer in Nigerian women. J Clin Oncol. 2018;36(28):2820.
   PubMed Web of Science ®Google Scholar
• Ambele MA, Van Zyl A, Pepper MS, Van Heerden MB, Van Heerden WFP. Amplification of 3q26. 2, 5q14. 3, 8q24. 3, 8q22. 3, and 14q32. 33 are possible common genetic alterations in oral cancer patients. Front Oncol. 2020;10:683.
   PubMed Web of Science ®Google Scholar
• Diseases N. National Cancer Registry; 2022. Available from: https://www.nicd.ac.za/centres/national-cancer-registry/. Accessed December 7, 2022.
   Google Scholar